Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 91 articles:
HTML format
Text format



Single Articles


    March 2017
  1. CICERO G, DE Luca R, Dorangricchia P, Dieli F, et al
    The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
    Anticancer Res. 2017;37:1475-1480.
    PubMed     Text format     Abstract available


  2. PALUMBO I, Matrone F, Montesi G, Bellavita R, et al
    Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study.
    Anticancer Res. 2017;37:1453-1457.
    PubMed     Text format     Abstract available


  3. HENKENBERENS C, VON Klot CA, Ross TL, Bengel FM, et al
    68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy.
    Anticancer Res. 2017;37:1273-1279.
    PubMed     Text format     Abstract available


  4. SCIALPI M, Prosperi E, D'Andrea A, Martorana E, et al
    Biparametric versus Multiparametric MRI with Non-endorectal Coil at 3T in the Detection and Localization of Prostate Cancer.
    Anticancer Res. 2017;37:1263-1271.
    PubMed     Text format     Abstract available


  5. ELLIS-CALEO T, Hegde JV, Bath S, Mesko S, et al
    Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer.
    Anticancer Res. 2017;37:1237-1242.
    PubMed     Text format     Abstract available


    February 2017
  6. MESSINA CS, Weiher H, Schmidt-Wolf IG
    Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide.
    Anticancer Res. 2017;37:555-559.
    PubMed     Text format     Abstract available


  7. LERTSUWAN K, Peters W, Johnson L, Lertsuwan J, et al
    Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells.
    Anticancer Res. 2017;37:529-537.
    PubMed     Text format     Abstract available


  8. ABLIN RJ, Owen S, Jiang WG
    Prostate Transglutaminase (TGase-4) Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells.
    Anticancer Res. 2017;37:481-487.
    PubMed     Text format     Abstract available


  9. FANDELLA A, Scattoni V, Galosi A, Pepe P, et al
    Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights.
    Anticancer Res. 2017;37:413-424.
    PubMed     Text format     Abstract available


    January 2017
  10. DONDOO TO, Fukumori T, Daizumoto K, Fukawa T, et al
    Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Anticancer Res. 2017;37:125-134.
    PubMed     Text format     Abstract available


    December 2016
  11. YAMAGUCHI H, Hori M, Suzuki O, Seo Y, et al
    Clinical Significance of the Apparent Diffusion Coefficient Ratio in Prostate Cancer Treatment with Intensity-modulated Radiotherapy.
    Anticancer Res. 2016;36:6551-6556.
    PubMed     Text format     Abstract available


  12. THELLENBERG-KARLSSON C, Nyman C, Nilsson S, Blom R, et al
    Bone-targeted Novel Cytotoxic Polybisphosphonate Conjugate in Castration-resistant Prostate Cancer: A Multicenter Phase 1 Study.
    Anticancer Res. 2016;36:6499-6504.
    PubMed     Text format     Abstract available


  13. STRANDBERG S, Karlsson CT, Ogren M, Axelsson J, et al
    11C-Acetate-PET/CT Compared to 99mTc-HDP Bone Scintigraphy in Primary Staging of High-risk Prostate Cancer.
    Anticancer Res. 2016;36:6475-6479.
    PubMed     Text format     Abstract available


  14. JOENSUU T, Joensuu G, Kairemo K, Kiljunen T, et al
    Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation.
    Anticancer Res. 2016;36:6439-6447.
    PubMed     Text format     Abstract available


  15. TSAI PH, Cheng CH, Lin CY, Huang YT, et al
    Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells.
    Anticancer Res. 2016;36:6367-6380.
    PubMed     Text format     Abstract available


    November 2016
  16. KATO H, Furuya Y, Miyazawa Y, Miyao T, et al
    Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:6141-6149.
    PubMed     Text format     Abstract available


  17. KIM SH, Kim KY, Yu SN, Park SG, et al
    Monensin Induces PC-3 Prostate Cancer Cell Apoptosis via ROS Production and Ca2+ Homeostasis Disruption.
    Anticancer Res. 2016;36:5835-5843.
    PubMed     Text format     Abstract available


  18. LAO L, Shen J, Tian H, Yao Q, et al
    Secreted Phosphoprotein 24 kD Inhibits Growth of Human Prostate Cancer Cells Stimulated by BMP-2.
    Anticancer Res. 2016;36:5773-5780.
    PubMed     Text format     Abstract available


  19. BURONI FE, Persico MG, Pasi F, Lodola L, et al
    Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:5719-5730.
    PubMed     Text format     Abstract available


    October 2016
  20. CHELLURI R, Caza T, Woodford MR, Reeder JE, et al
    Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models.
    Anticancer Res. 2016;36:5079-5086.
    PubMed     Text format     Abstract available


    September 2016
  21. OU YC, Weng WC, Chang KS, Mei CE, et al
    Prophylactic Robotic-assisted Laparoscopic Radical Prostatectomy for Preoperative Suspicion of Prostate Cancer: Experience with 55 Cases.
    Anticancer Res. 2016;36:4895-901.
    PubMed     Text format     Abstract available


  22. KULDA V, Topolcan O, Kucera R, Kripnerova M, et al
    Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Anticancer Res. 2016;36:4787-93.
    PubMed     Text format     Abstract available


  23. SMITH AD, Truong M, Bristow R, Yip P, et al
    The Utility of Serum CA9 for Prognostication in Prostate Cancer.
    Anticancer Res. 2016;36:4489-92.
    PubMed     Text format     Abstract available


  24. PORPIGLIA F, DE Luca S, Passera R, Manfredi M, et al
    Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score.
    Anticancer Res. 2016;36:4833-9.
    PubMed     Text format     Abstract available


  25. SHIDA Y, Hakariya T, Takehara K, Onita T, et al
    Comparison Between a Combined Transrectal and Transperineal Approach and a Transrectal Approach for Prostate Rebiopsy.
    Anticancer Res. 2016;36:4685-90.
    PubMed     Text format     Abstract available


    August 2016
  26. ZUGOR V, Kuhn R, Engelhard K, Poth S, et al
    The Value of Endorectal Magnetic Resonance Imaging of the Prostate in Improving the Detection of Anterior Prostate Cancer.
    Anticancer Res. 2016;36:4279-83.
    PubMed     Text format     Abstract available


  27. SINHA AA, Pomroy FE Jr, Wilson MJ
    Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:3847-54.
    PubMed     Text format     Abstract available


  28. KADONO Y, Nohara T, Kadomoto S, Nakashima K, et al
    Investigating Urinary Conditions Prior to Robot-assisted Radical Prostatectomy in Search of a Desirable Method for Evaluating Post-prostatectomy Incontinence.
    Anticancer Res. 2016;36:4293-8.
    PubMed     Text format     Abstract available


  29. ZUGOR V, Poth S, Kuhn R, Bernat MM, et al
    Is an Extended Prostate Biopsy Scheme Associated with an Improvement in the Accuracy Between the Biopsy Gleason Score and Radical Prostatectomy Pathology? A Multivariate Analysis.
    Anticancer Res. 2016;36:4285-8.
    PubMed     Text format     Abstract available


  30. DI PIERRO GB, Grande P, Mordasini L, Danuser H, et al
    Safety and Efficacy of Robot-assisted Radical Prostatectomy in a Low-volume Center: A 6-year Single-surgeon Experience.
    Anticancer Res. 2016;36:4201-7.
    PubMed     Text format     Abstract available


    July 2016
  31. SAKAUE M, Maeda K, Ohno S, Ito T, et al
    Screening for Identification of Personalized Food to Promote Adiponectin Secretion in Patients with Cancer.
    Anticancer Res. 2016;36:3673-7.
    PubMed     Text format     Abstract available


  32. KARIHTALA P, Rissanen T, Tuominen H
    Male Malignant Phyllodes Breast Tumor After Prophylactic Breast Radiotherapy and Bicalutamide Treatment: A Case Report.
    Anticancer Res. 2016;36:3433-6.
    PubMed     Text format     Abstract available


    June 2016
  33. ONISHI T, Shibahara T, Masui S, Sugino Y, et al
    Efficacy of Ethinylestradiol Re-challenge for Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:2999-3004.
    PubMed     Text format     Abstract available


  34. GRISANTI S, Antonelli A, Buglione M, Almici C, et al
    Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature.
    Anticancer Res. 2016;36:2975-81.
    PubMed     Text format     Abstract available


  35. MAKI S, Itoh Y, Kubota S, Okada T, et al
    Late Rectal Toxicity from Image-guided Intensity Modulated Radiotherapy for Prostate Cancer.
    Anticancer Res. 2016;36:2967-73.
    PubMed     Text format     Abstract available


    May 2016
  36. KANEMOTO A, Matsumoto Y, Sugita T, Abe E, et al
    Risk Factors and Time to Occurrence of Genitourinary Toxicity After External Beam Radiotherapy for Prostate Cancer.
    Anticancer Res. 2016;36:2441-4.
    PubMed     Text format     Abstract available


    April 2016
  37. CAPOUN O, Mikulova V, Jancikova M, Honova H, et al
    Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest(R) System for Detection of Circulating Tumor Cells.
    Anticancer Res. 2016;36:2019-26.
    PubMed     Text format     Abstract available


  38. DAVIES RS, Smith C, Lester JF
    Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
    Anticancer Res. 2016;36:1799-803.
    PubMed     Text format     Abstract available


  39. OU YC, Yang CK, Chang KS, Wang J, et al
    Prevention and Management of Complications During Robotic-assisted Laparoscopic Radical Prostatectomy Following Comprehensive Planning: A Large Series Involving a Single Surgeon.
    Anticancer Res. 2016;36:1991-8.
    PubMed     Text format     Abstract available


  40. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


    March 2016
  41. CUI YX, Evans BA, Jiang WG
    New Roles of Osteocytes in Proliferation, Migration and Invasion of Breast and Prostate Cancer Cells.
    Anticancer Res. 2016;36:1193-201.
    PubMed     Text format     Abstract available


  42. FRAGNI M, Bonini SA, Stabile A, Bodei S, et al
    Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells.
    Anticancer Res. 2016;36:913-20.
    PubMed     Text format     Abstract available


  43. WEEKS HP, Sanders AJ, Kynaston HG, Jiang WG, et al
    The Association Between WAVE1 and -3 and the ARP2/3 Complex in PC 3 Cells.
    Anticancer Res. 2016;36:1135-42.
    PubMed     Text format     Abstract available


  44. OWEN S, Sanders AJ, Mason MD, Jiang WG, et al
    Targeting of Receptor Activator of Nuclear Kappa B (RANK) in PC-3 Cells Increases Cell Proliferation and Matrix Adhesion In Vitro.
    Anticancer Res. 2016;36:1127-34.
    PubMed     Text format     Abstract available


    February 2016
  45. YENCILEK F, Yilmaz SG, Yildirim A, Gormus U, et al
    Apolipoprotein E Genotypes in Patients with Prostate Cancer.
    Anticancer Res. 2016;36:707-11.
    PubMed     Text format     Abstract available


  46. BURKE AJ, Ali H, O'Connell E, Sullivan FJ, et al
    Sensitivity Profiles of Human Prostate Cancer Cell Lines to an 80 Kinase Inhibitor Panel.
    Anticancer Res. 2016;36:633-41.
    PubMed     Text format     Abstract available


    January 2016
  47. YAMASAKI M, Yuasa T, Yamamoto S, Hayashi T, et al
    Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer.
    Anticancer Res. 2016;36:361-5.
    PubMed     Text format     Abstract available


  48. CHOI KW, Suh H, Oh HL, Ryou C, et al
    p21CIP1 Induces Apoptosis via Binding to BCL2 in LNCaP Prostate Cancer Cells Treated with MCS-C3, A Novel Carbocyclic Analog of Pyrrolopyrimidine.
    Anticancer Res. 2016;36:213-20.
    PubMed     Text format     Abstract available


  49. RAMACHANDRAN K, Speer C, Nathanson L, Claros M, et al
    Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer.
    Anticancer Res. 2016;36:161-8.
    PubMed     Text format     Abstract available


  50. ELGQVIST J, Timmermand OV, Larsson E, Strand SE, et al
    Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide 177Lu Compared to Alpha Particles and Gamma Rays.
    Anticancer Res. 2016;36:103-9.
    PubMed     Text format     Abstract available


  51. LINDHOLM PF, Hwang YS
    LPA Increases Tumor Growth and Bone Destruction Through Enhancement of Osteoclastogenic Cytokines.
    Anticancer Res. 2016;36:61-70.
    PubMed     Text format     Abstract available


    December 2015
  52. SHIOTA M, Takeuchi A, Sugimoto M, Kashiwagi E, et al
    Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
    Anticancer Res. 2015;35:6925-32.
    PubMed     Text format     Abstract available


  53. SPICK C, Polanec SH, Mitterhauser M, Wadsak W, et al
    Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.
    Anticancer Res. 2015;35:6787-91.
    PubMed     Text format     Abstract available


  54. RAATIKAINEN S, Aaaltomaa S, Karja V, Soini Y, et al
    Increased Peroxiredoxin 6 Expression Predicts Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy.
    Anticancer Res. 2015;35:6465-70.
    PubMed     Text format     Abstract available


    November 2015
  55. SCHALLIER D, Rappe B, Carprieaux M, Vandenbroucke F, et al
    Ureteral Metastasis: Uncommon Manifestation in Prostate Cancer.
    Anticancer Res. 2015;35:6317-20.
    PubMed     Text format     Abstract available


  56. RADES D, Conde-Moreno AJ, Cacicedo J, Segedin B, et al
    Metastatic Spinal Cord Compression: A Survival Score Particularly Developed for Elderly Prostate Cancer Patients.
    Anticancer Res. 2015;35:6189-92.
    PubMed     Text format     Abstract available


  57. SHIOTA M, Takeuchi A, Sugimoto M, Dejima T, et al
    Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
    Anticancer Res. 2015;35:6137-45.
    PubMed     Text format     Abstract available


  58. YENCILEK F, Yildirim A, Yilmaz SG, Altinkilic EM, et al
    Investigation of Interleukin-1beta Polymorphisms in Prostate Cancer.
    Anticancer Res. 2015;35:6057-61.
    PubMed     Text format     Abstract available


  59. MAIER GS, Horas K, Kurth AA, Lazovic D, et al
    Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma.
    Anticancer Res. 2015;35:6281-5.
    PubMed     Text format     Abstract available


    October 2015

  60. Synthesis and Vaccine Evaluation of the Tumor Associated Carbohydrate Antigen RM2 from Prostate Cancer.
    Anticancer Res. 2015;35:5714-5.
    PubMed     Text format    



  61. Focal Therapy of Prostate Cancer. An Emerging Strategy for Minimally Invasive, Staged Treatment.
    Anticancer Res. 2015;35:5714.
    PubMed     Text format    


  62. THALGOTT M, Rack B, Horn T, Heck MM, et al
    Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
    Anticancer Res. 2015;35:5679-85.
    PubMed     Text format     Abstract available


  63. DAVIES RS, Smith C, Button MR, Tanguay J, et al
    What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
    Anticancer Res. 2015;35:5615-21.
    PubMed     Text format     Abstract available


  64. ISHIKAWA H, Katoh H, Kaminuma T, Kawamura H, et al
    Carbon-ion Radiotherapy for Prostate Cancer: Analysis of Morbidities and Change in Health-related Quality of Life.
    Anticancer Res. 2015;35:5559-66.
    PubMed     Text format     Abstract available


  65. TOLKACH Y, Merseburger A, Herrmann T, Kuczyk M, et al
    Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.
    Anticancer Res. 2015;35:5443-51.
    PubMed     Text format     Abstract available


  66. UCHUGONOVA A, Zhang Y, Salz R, Liu F, et al
    Imaging the Different Mechanisms of Prostate Cancer Cell-killing by Tumor-targeting Salmonella typhimurium A1-R.
    Anticancer Res. 2015;35:5225-9.
    PubMed     Text format     Abstract available


  67. YAMAZAKI H, Nakamura S, Suzuki G, Yoshida K, et al
    Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy.
    Anticancer Res. 2015;35:5167-77.
    PubMed     Text format     Abstract available


  68. AMBROSIO MR, Rocca BJ, Barone A, Ginori A, et al
    Lymphatic Vascularization in Prostate Adenocarcinoma: Correlation with Tumor Grade, Androgen Withdrawal and Prognosis.
    Anticancer Res. 2015;35:5595-600.
    PubMed     Text format     Abstract available


  69. NOLTE E, Sobel A, Wach S, Hertlein H, et al
    The New Semisynthetic Cardenolide Analog 3beta-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines.
    Anticancer Res. 2015;35:5271-5.
    PubMed     Text format     Abstract available


    September 2015
  70. KITAGAWA Y, Urata S, Mizokami A, Nakashima K, et al
    Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study.
    Anticancer Res. 2015;35:5031-6.
    PubMed     Text format     Abstract available


  71. KIM Y, Wei J, Citronberg J, Hartman T, et al
    Relation of Vitamin E and Selenium Exposure to Prostate Cancer Risk by Smoking Status: A Review and Meta-Analysis.
    Anticancer Res. 2015;35:4983-96.
    PubMed     Text format     Abstract available


  72. FUCHSOVA R, Topolcan O, Windrichova J, Hora M, et al
    PHI in the Early Detection of Prostate Cancer.
    Anticancer Res. 2015;35:4855-7.
    PubMed     Text format     Abstract available


  73. BAMJI ZD, Washington KN, Akinboye E, Bakare O, et al
    Apoptotic Effects of Novel Dithiocarbamate Analogs of Emetine in Prostate Cancer Cell Lines.
    Anticancer Res. 2015;35:4723-32.
    PubMed     Text format     Abstract available


    July 2015
  74. GIRELLI G, Franco P, Sciacero P, Cante D, et al
    Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function.
    Anticancer Res. 2015;35:4177-82.
    PubMed     Text format     Abstract available


  75. ALANEE S, Moore A, Nutt M, Holland B, et al
    Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer.
    Anticancer Res. 2015;35:4145-50.
    PubMed     Text format     Abstract available


  76. WINCHESTER D, Ricks-Santi L, Mason T, Abbas M, et al
    SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.
    Anticancer Res. 2015;35:3811-9.
    PubMed     Text format     Abstract available


  77. BANKS M, Holick MF
    Molecular Mechanism(s) Involved in 25-Hydroxyvitamin D's Antiproliferative Effects in CYP27B1-transfected LNCaP Cells.
    Anticancer Res. 2015;35:3773-9.
    PubMed     Text format     Abstract available


    June 2015
  78. HEIDEGGER I, Klocker H, Pichler R, Horninger W, et al
    PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
    Anticancer Res. 2015;35:3567-70.
    PubMed     Text format     Abstract available


  79. TANJI N, Kikugawa T, Ochi T, Taguchi S, et al
    Circulating Cytokine Levels in Patients with Prostate Cancer: Effects of Neoadjuvant Hormonal Therapy and External-beam Radiotherapy.
    Anticancer Res. 2015;35:3379-83.
    PubMed     Text format     Abstract available


  80. MACKIEWICZ J, Kazimierczak U, Kotlarski M, Dondajewska E, et al
    Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model.
    Anticancer Res. 2015;35:3275-88.
    PubMed     Text format     Abstract available


  81. GODA AE, Erikson RL, Ahn JS, Kim BY, et al
    Induction of G1 Arrest by SB265610 Involves Cyclin D3 Down-regulation and Suppression of CDK2 (Thr160) Phosphorylation.
    Anticancer Res. 2015;35:3235-43.
    PubMed     Text format     Abstract available


    May 2015

  82. Technical aspects of focal therapy in localized prostate cancer.
    Anticancer Res. 2015;35:3114.
    PubMed     Text format    


  83. PETRIOLI R, Francini E, Fiaschi AI, Laera L, et al
    Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of >/=85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.
    Anticancer Res. 2015;35:3097-102.
    PubMed     Text format     Abstract available


  84. BOURDOUMIS A, Chrisofos M, Stasinou T, Christopoulos P, et al
    The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Anticancer Res. 2015;35:3075-9.
    PubMed     Text format     Abstract available


  85. TRAMACERE F, Arcangeli S, Pignatelli A, Castagna R, et al
    Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Anticancer Res. 2015;35:3049-54.
    PubMed     Text format     Abstract available


  86. SILVA TB, Oliveira CZ, Faria EF, Mauad EC, et al
    Development and validation of a nomogram to estimate the risk of prostate cancer in Brazil.
    Anticancer Res. 2015;35:2881-6.
    PubMed     Text format     Abstract available


  87. FARUQUE MU, Paul R, Ricks-Santi L, Jingwi EY, et al
    Analyzing the Association of Polymorphisms in the CRYBB2 Gene with Prostate Cancer Risk in African Americans.
    Anticancer Res. 2015;35:2565-70.
    PubMed     Text format     Abstract available


  88. ZIEBA J, Ksiazkiewcz M, Janik K, Banaszczyk M, et al
    Sensitivity of neoplastic cells to senescence unveiled under standard cell culture conditions.
    Anticancer Res. 2015;35:2759-68.
    PubMed     Text format     Abstract available


  89. YANG M, Jiang P, Hoffman RM
    Early Reporting of Apoptosis by Real-time Imaging of Cancer Cells Labeled with Green Fluorescent Protein in the Nucleus and Red Fluorescent Protein in the Cytoplasm.
    Anticancer Res. 2015;35:2539-43.
    PubMed     Text format     Abstract available


  90. HEIDEGGER I, Borena W, Pichler R
    The role of human papilloma virus in urological malignancies.
    Anticancer Res. 2015;35:2513-9.
    PubMed     Text format     Abstract available


    April 2015
  91. MAHMOOD S, Vu K, Tai P, Joseph K, et al
    Radiation-induced second malignancies.
    Anticancer Res. 2015;35:2431-4.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: